Abstract Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate
with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd), has been …

Antibody-drug conjugates (ADCs) are targeted therapies, mainly used in oncology,
consisting in a three-component molecular architecture combining a highly potent drug …

Key defining attributes of an antibody–drug conjugate (ADC) include the choice of the
targeting antibody, linker, payload, and the drug‐to‐antibody ratio (DAR). Historically, most …

Epidermal growth factor receptor (EGFR) is a validated tumor marker overexpressed in
various cancers such as squamous cell carcinoma (SSC) of the head and neck and gliomas …

Existing antibody–drug conjugate (ADC) linkers, whether cleavable or non‐cleavable, are
designed to release highly toxic payloads or payload derivatives upon internalisation of the …

Abstract Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC),
comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7–8 with the topoisomerase I …

Attaching a cytotoxic “payload” to an antibody to form an antibody–drug conjugate (ADC)
provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the …

A crucial design feature for the therapeutic success of antibody-drug conjugates (ADCs) is
the linker that connects the antibody with the drug. Linkers must be stable in circulation and …

Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells
through internalization and lysosomal trafficking has emerged as an effective cancer …

Stimuli-responsive polymer-drug conjugates (PDCs) provide promising approaches in
anticancer treatment. Here, we report the synthesis and biological evaluation of PDCs made …